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Cilostazol is a phosphodiesterase-3 inhibitor and is known to have pleiotropic effects including anti-
platelet and vasodilatation effects and protective effects on endothelial cells. Cilostazol also reportedly
reduced stroke recurrence, poststroke intracranial hemorrhage, and extracranial bleeding in a meta-
analysis. Although it is known that cilostazol has the potential to suppress hemorrhagic stroke, the
precise mechanisms remained unclear. Therefore, we evaluated the protective effects and mechanisms of
cilostazol against hemorrhagic stroke. We found that cilostazol prevented the hemorrhagic trans-
formation induced by focal cerebral ischemia in mice treated with intravenous tissue plasminogen
activator or warfarin via protecting endothelial cells and tight junction proteins. We also demonstrated
that cilostazol attenuated collagenase-induced intracranial hemorrhage in mice. In vitro studies showed
that endothelial cells, pericytes, tight junction proteins, adherence junction proteins, and the basement
membrane, which are all components of the blood-brain barrier, were protected by the administration of
cilostazol following collagenase injury. These results suggested that cilostazol reduces hemorrhagic
stroke by protecting the entire blood-brain barrier. Here, we review the protective effects of cilostazol on
the blood-brain barrier that result in the prevention of hemorrhagic stroke, discuss the results we ob-
tained using multiple hemorrhagic stroke models, and introduce potential future applications of
cilostazol.
© 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Cilostazol is a phosphodiesterase-3 inhibitor that has been
approved for use as a vasodilating antiplatelet drug in the treat-
ment of ischemic symptoms in chronic peripheral arterial
obstruction or intermittent claudication and for the secondary
prevention of cerebral infarction in Asia. Recently, cilostazol was
reported to be more effective than aspirin in the secondary pre-
vention of all types of stroke, especially secondary hemorrhagic
stroke, in a clinical trial (cilostazol for the prevention of secondary
stroke [CSPS 2]) andmeta-analysis (1,2). According to these reports,
cilostazol has the potential to reduce hemorrhagic stroke.
Currently, only a few treatment strategies for hemorrhagic
stroke exist. However, there is no effective treatment for thermacological Society.
g by Elsevier B.V. on behalf of Japa
d/4.0/).hemorrhagic transformation (HT) that occurs after the adminis-
tration of intravenous tissue plasminogen activator (tPA) or anti-
coagulation therapies like warfarin. Moreover, early decreases in
blood pressure are reportedly the only effective treatment for
intracranial hemorrhages (ICHs) (3).
In addition to the limited treatment strategies for hemorrhagic
stroke, the administration of antiplatelet drugs and anticoagulants
that is popular in clinical situations can increase the risk of hem-
orrhagic complications. For instance, it has been reported that one
third of patients with ICHwere administrated antiplatelet drugs (4).
The blood-brain barrier (BBB) is composed of a basement
membrane, endothelial cells, pericytes, and tight junction proteins
and plays an important role as a part of the neurovascular unit (5).
Protection of the BBB is expected to be an important strategy for
developing neuroprotective drugs (6). However, it remains unclear
whether protecting the BBB can help reduce hemorrhagic stroke.
Before the CSPS 2 study and meta-analysis were published, we
focused mainly on examining the protective effects of cilostazol
against brain ischemia; accordingly, we demonstrated thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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T. Takagi, H. Hara / Journal of Pharmacological Sciences 131 (2016) 155e161156protective effects of cilostazol against HT after transient cerebral
ischemia (7). Based on previous studies, we hypothesized that cil-
ostazol would be able to suppress hemorrhagic stroke by protecting
the BBB, and we tested this hypothesis using various hemorrhagic
stroke models. Here, we review what is known about the pleio-
tropic effects of cilostazol, report on the results we obtained using
the various stroke models, and provide some suggestions for using
cilostazol in the future (see Table 1).
2. Pleiotropic effects of cilostazol in basic research
2.1. Protection of endothelial cells
Many reports have demonstrated the protective effects of cil-
ostazol on endothelial cells. For instance, cilostazol was shown to
exert its protective effects on endothelial cells by increasing
endothelial nitric oxide synthase activity (8). Moreover, cilostazol
exerted protective effects against oxidative stress induced-
endothelial senescence and dysfunction via the upregulation of
Sirt1 (9). Oyama et al. reported that cilostazol reduced ischemic
brain injury by protecting endothelial cells in spontaneously hy-
pertensive rats (10). Collectively, these results indicate that cil-
ostazol protects endothelial cells from damage in stroke.
2.2. Effects on vascular smooth muscle cells
Recently, it was reported that cilostazol prevents endothelin-
induced smooth muscle constriction and proliferation (11). Except
for its effect on vasoconstriction, cilostazol reportedly inhibits the
abnormal proliferation of vascular smooth muscle cells (12). These
results indicate that cilostazol also has a protective effect on
vascular smooth muscle cells.
2.3. Protection of the BBB
Cilostazol also appears to have protective effects on the BBB.
In vivo studies indicated that cilostazol exerts its neuroprotective
effects in cerebral infarction by protecting the BBB (7,13). Omote
et al. demonstrated that the administration of cilostazol reduced
the spontaneous infarct volume and preserved motor and spatial
cognitive functions in stroke-prone spontaneously hypertensive
rats (14). These results suggest that cilostazol has the potential to
protect the BBB and exert pleiotropic effects on stroke.
Based on many basic research studies, cilostazol is expected to
protect endothelial cells, vascular smooth muscle cells, and the
entire BBB from various types of damage. It is suggested that pro-
tection of the BBB could result in decreased hemorrhagic stroke,
however, only a few studies on the protective effects of cilostazol
against hemorrhagic stroke exist.
3. Recent clinical studies with cilostazol
As mentioned above, the CSPS 2 trial demonstrated that cil-
ostazol is more effective than aspirin in the secondary prevention of
all types of stroke, especially secondary hemorrhagic stroke (1).
Cilostazol can also reduce stroke recurrence, poststroke ICH, and
extracranial bleeding according to a meta-analysis (2). Additionally,
a recent study showed that cilostazol exhibited beneﬁcial effects on
the outcome of patients with small vessel infarction (15).
A randomized clinical trial that compared the effects of cil-
ostazol plus aspirin vs. aspirin alone on the progression of intra-
cranial arterial stenosis (IAS) was published at 2015 (CATHARSIS).
In that trial, no signiﬁcant differences in IAS progression were
observed between the two groups because the progression of IAS
appears to be less frequent. However, the annual incidence rates of
T. Takagi, H. Hara / Journal of Pharmacological Sciences 131 (2016) 155e161 157all vascular events, stroke, and ischemic stroke tended to be lower
in the cilostazol plus aspirin group than in the group treated with
aspirin alone. The results of the CATHARSIS trial suggest the po-
tential utility of developing pharmacotherapies that combine cil-
ostazol plus aspirin for managing symptomatic IAS (16).
Cilostazol has also attracted attention with regards to its po-
tential to prevent restenosis in clinical situations. Cilostazol reduces
angiographic restenosis after endovascular therapy for femo-
ropopliteal lesions (17). In coronary disease, the addition of cil-
ostazol to conventional dual antiplatelet therapy reportedly
reduces the risk of cardiac events and restenosis after drug-eluting
stent implantation (18).
In summary, cilostazol was better at reducing hemorrhagic
stroke compared to aspirin. However, recent clinical reports
focused on the effects of cilostazol on in-stent restenosis and found
that the effects resulted from endothelial protection and the inhi-
bition of vascular smooth muscle proliferation. Currently, no clin-
ical trials have focused on the inhibitory effects of cilostazol on
hemorrhagic stroke; however, this type of clinical trial is needed to
conﬁrm the protective effects of cilostazol against hemorrhagic
stroke.4. Protective effects of cilostazol against tPA-induced HT
Accumulating evidence suggests that thrombolysis is beneﬁcial
for patients with ischemic stroke if it is administered during the
ﬁrst 4.5 h after symptom onset; however, delayed thrombolysis was
related to an increased risk of HT, which aggravated the clinical
outcome in patients with acute ischemic brain attacks. Currently,
there are no approved treatments for tPA-associated HT. Edaravone
has been reported to have the potential to protect the BBB from
ischemia-reperfusion injury and tPA toxicity (19), but has not been
established as a treatment for hemorrhagic complications. There-
fore, in a previous publication, we evaluated whether cilostazol
would prevent tPA-associated HT (20).
In that study, mice subjected to 6-h middle cerebral artery oc-
clusion (MCAO) were treated with delayed intravenous tPA alone,
tPA plus cilostazol, or vehicle before reperfusion. We evaluated the
histological changes in the hemorrhage, performed hemoglobinVehicle tPA tPA +
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Fig. 1. The effect of cilostazol against tPA-induced HT. Modiﬁed from Ishiguro et al. (20) Hist
after MCAO (B). Data are expressed as the mean ± the standard deviation (SD). *p < 0.05 vs
assay at 24 h after MCAO. Data are expressed as the mean ± SD. *p < 0.05 vs. vehicle, #p < 0.0
induced HT.assays to measure the hemorrhage volume, and determined the
level of matrix metalloproteinase-9 (MMP-9) activation.
The results showed that HT was signiﬁcantly induced by tPA
administration 6 h after the onset of ischemia. The combination of
tPA plus cilostazol at 6 h signiﬁcantly ameliorated the severity of HT
(Fig. 1A, B). The MMP-9 activity was signiﬁcantly decreased by tPA
plus cilostazol at 6 h (Fig. 1C). These results indicated that cilostazol
prevented the HT that was induced by focal cerebral ischemia in
mice treated with tPA by protecting the endothelial cells and
reducing MMP-9 (20).
Kasahara et al. also reported that treatment with cilostazol for 7
days before ischemia signiﬁcantly suppressed the risk and severity
of cerebral hemorrhaging after the injection of tPA and suppressed
the microvasculature disruption in the ischemic area that is asso-
ciated with reduced MMP-9 activity (21).
It is well known that MMP-9 activation causes the deterioration
of tight junctions, which enhances the permeability and decreases
the structural integrity of the BBB (22). It has also been suggested
that MMP-9 activation in endothelial cells injured by ischemia-
reperfusion is a mechanism underlying tPA-induced HT (23). In
addition to these previous reports, the two results (20,21)
mentioned above suggest that tPA itself is neurotoxic and results
in impairment of the endothelial cells and tight junction proteins
through MMP-9 activation. Such impairment of the endothelial
cells and tight junction proteins causes BBB disruption; however,
cilostazol has the potential to prevent this BBB disruption by sup-
pressing MMP-9 activation in injured endothelial cells (Fig. 1D).5. Protective effects of cilostazol against warfarin-induced HT
Warfarin is widely used to prevent cardio-embolic ischemic
stroke, but it has the potential to exacerbate HT after cerebral
ischemia. Previously, we investigated whether cilostazol is capable
of suppressing warfarin-induced HT after cerebral ischemia in mice
(24).
Mice were treated with oral warfarin before a 3-h MCAO, which
was followed by a 21-h reperfusion to induce HT. The brain he-
moglobin content was evaluated 24 h after MCAO. We also CSZ
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T. Takagi, H. Hara / Journal of Pharmacological Sciences 131 (2016) 155e161158evaluated the proteins involved in vascular endothelial integrity
using western blotting.
The results showed that the HT volume was exacerbated by
warfarin treatment and that cilostazol suppressed this exacerba-
tion (Fig. 2A). Furthermore, cilostazol upregulated the expression of
tight junction proteins and vascular endothelial cadherin (VE-
cadherin) (Fig. 2B). These ﬁndings indicated that cilostazol reduced
the warfarin-related risk of HT after ischemia by protecting the VE-
cadherin and tight junction proteins. In this study, MMP-9 was not
increased by warfarin treatment, but cilostazol protected tight
junction proteins and VE-cadherin (24).
Unlike tPA-induced HT, activation of MMP-9 was not detected in
warfarin-induced HT. The deterioration of tight junction proteins
and VE-cadherin was exacerbated by warfarin treatment, and was
thus suggested as a mechanism of warfarin-induced HT. Cilostazol
could prevent warfarin-induced hemorrhagic stroke by protecting
tight junction and adherence junction proteins (Fig. 2C). Theseﬁndings suggest that cilostazol reduces hemorrhage volume by
exerting protective effects on vascular endothelial cells.
6. Cilostazol protects against collagenase-induced ICH by
protecting the BBB
Based on the results of the two abovementioned examinations
(20,24), we evaluated the effects of cilostazol pre-treatment on the
collagenase-induced ICH volume and BBB permeability in mice in a
previous publication (25). We also evaluated various vascular
components in vitro, including endothelial cells, vascular smooth
muscle cells, pericytes, and a co-culture model.
Our results showed that pre-treatment with cilostazol reduced
the ICH volume compared to vehicle (Fig. 3A). BBB permeability
was increased by collagenase-induced ICH, and cilostazol attenu-
ated the BBB leakage (Fig. 3B). Electron microscope images showed
that the coverage rate of pericytes for endothelial cells was
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T. Takagi, H. Hara / Journal of Pharmacological Sciences 131 (2016) 155e161 159improved by the cilostazol administration (Fig. 3C). In vitro exper-
iments showed that cilostazol prevented both endothelial cells and
pericytes from collagenase-induced cell death. Cilostazol also pro-
tected tight junction proteins, adherence junction proteins, and thebasement membrane from collagenase-induced injury according to
western blot analyses (25). Therefore, cilostazol likely reduces the
collagenase-induced ICH volume by protecting the entire BBB
(Fig. 3D).
T. Takagi, H. Hara / Journal of Pharmacological Sciences 131 (2016) 155e161160Collagenase impairs endothelial cells, pericytes, and other BBB
components like the basement membrane and tight junction pro-
teins. The ability of cilostazol to decrease hematoma size is likely a
result of its protective effects on both endothelial cells and pericytes.
Cilostazol is thought to activate cyclic adenosine monophosphate
(cAMP) response element binding protein (CREB) phosphorylation
through cAMP/protein kinase A signaling and protects both endo-
thelial cells and pericytes from collagenase-induced cell death,
which may result in increased extracellular matrix.
In addition to our report, Torii et al. indicated that cilostazol
prevented an increase in the endothelial permeability by preser-
ving the actin cytoskeleton and the redistribution of junctional
proteins in hypoxia/reoxygenation (26). Collectively, previous re-
ports on the protective effects of cilostazol on the BBB support that
cilostazol can protect all components of the BBB, thus reducing the
ICH volume. Such ﬁndings suggest that cilostazol has the potential
to reduce hemorrhagic stroke, as predicted in clinical trials.
7. Future perspectives of cilostazol
7.1. Effects of cilostazol on vascular dementia
Cilostazol reportedly has the potential to suppress cognitive
decline in patients withmild dementiawho are receiving donepezil
(27). After the publication of that report, other studies began
examining the effects of cilostazol on vascular dementia. A study by
Kumar et al. investigated the potential applications of cilostazol for
diabetes-induced vascular dementia by using streptozotocin to
induce diabetes and subsequent vascular dementia in Wistar rats.
They found that treatment with cilostazol signiﬁcantly attenuated
the diabetes-induced learning and memory impairments and
endothelial dysfunction (28).
Moreover, a study by Kwon et al. tested whether cognitive
impairment could be exacerbated in a combined injury by using a
rat model of chronic cerebral hypoperfusion with diabetes. They
also investigated the protective effects of cilostazol against cogni-
tive impairment. The authors demonstrated that there are delete-
rious interactions between chronic cerebral hypoperfusion and
type II diabetes mellitus and found that cilostazol ameliorated the
cognitive impairments in rats with diabetes mellitus and
hypoperfusion-induced dementia (29).
These results indicated that cilostazol could improve the
memory impairments directly through inhibition of neuronal cell
death via the upregulation of phospho-CREB and brain-derived
neurotrophic factor; moreover, cilostazol could indirectly atten-
uate the learning and memory impairments by improving endo-
thelial dysfunction.
7.2. Effects of cilostazol on cerebral beta amyloid drainage
Maki et al. reported that cilostazol rescued the cognitive deﬁcits
in a transgenic mouse (Tg-SwDI mice) model of cerebrovascular
beta-amyloidosis. Additionally, they demonstrated that cilostazol
treatment maintained cerebral hyperemic and vasodilative re-
sponses, suppressed the degeneration of pericytes and vascular
smooth muscle cells, and promoted the perivascular drainage of
soluble Ab1e40 (30). These results suggest that cilostazol might be
a candidate for suppressing cognitive impairment in Alzheimer's
disease or vascular dementia and imply that these neuroprotective
effects were exerted through protection of the BBB.
8. Conclusion
Recent clinical and basic research studies showed that the
phosphodiesterase-3 inhibitor cilostazol has pleiotropic effects.Cilostazol can protect endothelial cells, vascular smooth muscle
cells, pericytes, the basement membrane, tight junction proteins,
and adherence junction proteins fromvarious types of damage. As a
result of its multiple effects, cilostazol can suppress hemorrhagic
stroke by protecting all of the components of the BBB. A clinical trial
that focuses on the ability of cilostazol to suppress bleeding is
needed to apply the results of basic research studies to clinical
practice. The effects of cilostazol on stroke may also be extended to
cognitive impairments in the future.
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